FBR & Co Reiterates “Sell” Rating for Alexion Pharmaceuticals Inc. (ALXN)
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)‘s stock had its “sell” rating reiterated by FBR & Co in a report released on Friday.
A number of other research analysts also recently issued reports on the stock. Brean Capital began coverage on shares of Alexion Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $221.00 price target for the company. Vetr upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating and set a $107.00 price target for the company in a research note on Thursday, September 29th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 27th. Leerink Swann lifted their price target on shares of Alexion Pharmaceuticals from $210.00 to $211.00 and gave the stock an “outperform” rating in a research note on Monday, September 26th. Finally, Jefferies Group decreased their price target on shares of Alexion Pharmaceuticals from $140.00 to $120.00 and set a “hold” rating for the company in a research note on Friday, September 23rd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $178.32.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 1.76% during mid-day trading on Friday, hitting $125.05. 1,018,595 shares of the stock were exchanged. Alexion Pharmaceuticals has a 52-week low of $110.56 and a 52-week high of $193.45. The firm has a market cap of $28.04 billion, a price-to-earnings ratio of 314.20 and a beta of 1.33. The company has a 50 day moving average price of $127.95 and a 200 day moving average price of $134.91.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/fbr-co-reiterates-sell-rating-for-alexion-pharmaceuticals-inc-alxn.html
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. The firm earned $753 million during the quarter, compared to analysts’ expectations of $743.18 million. During the same quarter in the prior year, the firm earned $1.44 EPS. The firm’s revenue was up 18.4% compared to the same quarter last year. On average, analysts anticipate that Alexion Pharmaceuticals will post $4.67 EPS for the current year.
In other Alexion Pharmaceuticals news, Director Alvin S. Parven sold 15,000 shares of the company’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $136.53, for a total value of $2,047,950.00. Following the transaction, the director now directly owns 6,373 shares in the company, valued at approximately $870,105.69. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Leonard Bell sold 1,010 shares of the company’s stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $137.14, for a total transaction of $138,511.40. Following the completion of the transaction, the director now owns 405,289 shares in the company, valued at $55,581,333.46. The disclosure for this sale can be found here. 4.41% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Glenmede Trust Co. NA raised its position in Alexion Pharmaceuticals by 38.1% in the first quarter. Glenmede Trust Co. NA now owns 3,077 shares of the biopharmaceutical company’s stock worth $427,000 after buying an additional 849 shares during the period. Virginia Retirement System purchased a new position in Alexion Pharmaceuticals during the first quarter worth about $509,000. Nikko Asset Management Americas Inc. purchased a new position in Alexion Pharmaceuticals during the first quarter worth about $297,000. NN Investment Partners Holdings N.V. purchased a new position in Alexion Pharmaceuticals during the first quarter worth about $9,685,000. Finally, TimesSquare Capital Management LLC raised its position in Alexion Pharmaceuticals by 430.2% in the first quarter. TimesSquare Capital Management LLC now owns 39,555 shares of the biopharmaceutical company’s stock worth $5,507,000 after buying an additional 32,095 shares during the period. Institutional investors own 96.34% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.